TxCell appoints Dr. Olivier Danos to its Scientific Advisory Board.
M2 EQUITYBITES-August 25, 2016-TxCell appoints Dr. Olivier Danos to its Scientific Advisory Board
(C)2016 M2 COMMUNICATIONS http://www.m2.com
TxCell SA (Paris:TXCL), a biotechnology company, announced on Wednesday that it has appointed Olivier Danos, PhD to its Scientific Advisory Board (SAB).
Considered to be a world-leading expert in the field of gene therapy for haematological and neurological diseases, Dr Danos is currently senior vice president of Cell and Gene Therapy at Biogen and.
Dr Danos has led Biogen's gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering, since 2014. Prior to Biogen, he served as senior vice president, Molecular Medicine, Synthetic Biology and Gene Regulation, at Kadmon Pharmaceuticals, from 2011 to 2014. Before Kadmon, he was the director of the Gene Therapy Consortium at University College, London, and led a gene therapy research team at the Necker Hospital - Enfants Malades in Paris. Earlier, he was scientific director of Genethon and senior research director with the CNRS in France.
According to TxCell, Dr Danos is another significant addition to its SAB, which already includes leading experts in immunology, T-cell biology and chimeric antigen receptors. TxCell created its SAB in March 2016 with the appointment of the first three members.
Currently, the company SAB is now composed of four world-leading immunology experts, including Prof. Zelig Eshhar, who recently received the Novartis Prize for Clinical Immunology
TxCell is developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases.
((Comments on this story may be sent to firstname.lastname@example.org))